Moneycontrol
HomeNewsIndiaCoronavirus Mumbai update: Tata Institute expects 50% of city population to develop herd immunity by January
Trending Topics

Coronavirus Mumbai update: Tata Institute expects 50% of city population to develop herd immunity by January

The TIFR team expects coronavirus herd immunity to increase gradually and the city to become fully operational by around November 1.

September 07, 2020 / 17:42 IST
Story continues below Advertisement

According to a report submitted to the Brihanmumbai Municipal Corporation (BMC), nearly 75 percent of people living in slum pockets in Mumbai and 50 percent of those residing in non-slum pockets would develop antibodies by December or January.

The study, published by the Tata Institute of Fundamental Research (TIFR), however, has not considered the threat of reinfection, which has emerged as a concern after the first confirmed case of reinfection in India was reported in Bengaluru.

Story continues below Advertisement

A private hospital has reported that a 27-year-old woman from Bengaluru tested positive again nearly a month after she was treated and discharged from the hospital.

Track this LIVE blog for all the latest updates on coronavirus pandemic

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show